Akebia Therapeutics (AKBA) Payables: 2016-2025
Historic Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $10.1 million.
- Akebia Therapeutics' Payables fell 25.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 1.27%. This contributed to the annual value of $15.2 million for FY2024, which is 3.72% up from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Payables is $10.1 million, which was down 12.70% from $11.6 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Payables ranged from a high of $42.0 million in Q2 2021 and a low of $9.0 million during Q3 2023.
- In the last 3 years, Akebia Therapeutics' Payables had a median value of $11.9 million in 2024 and averaged $12.1 million.
- As far as peak fluctuations go, Akebia Therapeutics' Payables tumbled by 54.14% in 2023, and later skyrocketed by 49.30% in 2024.
- Over the past 5 years, Akebia Therapeutics' Payables (Quarterly) stood at $33.6 million in 2021, then crashed by 46.35% to $18.0 million in 2022, then dropped by 18.79% to $14.6 million in 2023, then grew by 3.72% to $15.2 million in 2024, then fell by 25.25% to $10.1 million in 2025.
- Its last three reported values are $10.1 million in Q3 2025, $11.6 million for Q2 2025, and $12.7 million during Q1 2025.